Skip to main content
. 2018 Dec 19;30(2):250–258. doi: 10.1093/annonc/mdy540

Figure 2.

Figure 2.

(A) Best change from baseline in the sum of longest target lesion diameters in each patient receiving nivolumab plus SOX. (B) Best change from baseline in the sum of longest target lesion diameters in each patient receiving nivolumab plus CapeOX. (C) Percent change in sum of longest diameters of target lesion from baseline in each patient receiving nivolumab plus SOX. (D) Percent change in sum of longest diameters of target lesion from baseline in each patient receiving nivolumab plus CapeOX (central assessment) (FAS population). CapeOX, capecitabine plus oxaliplatin; FAS, full analysis set; PD-L1, programmed death-ligand 1; SOX, S-1 (tegafur–gimeracil–oteracil potassium) plus oxaliplatin.